An observational study in Valvular Heart Disease and Coronary Artery Disease, sponsored by Cambridge University Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Cambridge University Hospitals NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Heart Valve Diseases with a site in United Kingdom — 16 open to participants now, 21 under way, none of them phase 3. Heart Valve Diseases · United Kingdom.
Among the 42 studies in Heart Valve Diseases with a site in United Kingdom, this one is the 6th largest by planned enrollment of the 18 observational ones that give a count, is the only one that started in 2026, is one of 18 observational ones, reaches primary completion later than 15 of the 20 other live ones, and was the 42nd registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →16 of the 42 studies in Heart Valve Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–90
Imperial College London · Sites in United Kingdom
Ages 18+
Edwards Lifesciences · Sites in United Kingdom, Germany, Greece and 3 more countries
Abbott Medical Devices · Sites in United Kingdom, United States, Denmark and 7 more countries
University of Leicester · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 300 across 228 observational studies indexed under Heart Valve Diseases.
Median enrollment 207 across the 24 interventional studies, 400 across the 18 observational. Of the 19 that completed or were terminated, 8 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 42 have an industry lead sponsor. The 10 most frequent:
Cambridge University Hospitals NHS Foundation Trust is the lead sponsor of 172 studies on the registry; 39 are open to participants now.
Cambridge University Hospitals NHS Foundation Trust has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Valve Diseases with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT07057466Imperial College LondonProspective Evaluation of AI-ECG for SHD Detection | 2027-05-03 |
| NCT06602609Imperial College LondonRemote Cardiovascular Monitoring in Post-TAVI Patients | 2027-07-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 42 studies in Heart Valve Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
There are many types of heart disease. Two of the most common causes are narrowings within the blood vessels that supply the heart (known as coronary artery disease), or valves within the heart becoming narrowed (stenosed) or leaky (regurgitation), known as heart valve disease.
There are two main types of imaging used to test for these conditions. Coronary artery disease can be diagnosed by taking X-ray pictures of a dye when injected into the blood vessels. In some cases the dye is injected into the veins and a CT scanner is used (CT coronary angiography), in others the dye is injected via a tube placed in the artery (invasive coronary angiography). Valvular heart disease is normally diagnosed using an echocardiogram (ultrasound of the heart).
In this study the investigators are looking for subtle changes in the sounds that come from the heart, which may allow heart disease to be detected earlier. The investigators are using a novel device, similar to a digital stethoscope, that has excellent sensitivity for heart sounds. Ultimately this may be used in community settings including GP surgeries, in this study the investigators are collecting sounds from patients undergoing routine scans as part of their workup for heart disease.
Patients referred to Department of Cardiology, Cambridge University NHS Foundation Trust.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No valvular heart disease, no coronary artery disease
Significant coronary artery disease, no valvular heart disease
Significant valvular heart disease, no coronary artery disease
Significant coronary artery disease and significant valvular heart disease
Discriminant score
A discriminant score (minimum 0, maximum 1) for each of coronary artery disease and valvular heart disease will be generated by analysis of the phonographs.
Time frame: Investigations to be performed within six (6) months of one another.
Plan to share: Undecided — To reviewed following completion of pilot phase.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.
Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 18 months is below that.
Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.
Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2026, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cambridge University Hospitals NHS Foundation Trust →